These combination products typically include a GLP-1 receptor agonist alongside herbal ingredients, vitamins, or other compounds
The systemic effects on salivary function remain the same regardless of where the needle goes
The team analyzed electronic health records of 606,434 U.S
EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Agrawal N, Wanner C, Green JB, et al
This approval marked the first oral GLP-1 RA indicated specifically for obesity, creating a new option for patients and clinicians who prefer or require non-injectable therapies, in contrast to Rybelsus, an oral semaglutide approved for the treatment of type 2 diabetes
The SURMOUNT-1 trial for tirzepatide showed average weight loss of 15% of starting body weight at 36 weeks (roughly 8.5 months)